Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 11;10:879192. doi: 10.3389/fbioe.2022.879192

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Ma, Yin, Hao, Liu, Shi, Diao, Yu, Liu, Chen and Zhong.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Effect of combination treatment with hucMSC-Exos and autophagy regulators on corneal clinical and pathological examination. (A,B) Corneal fluorescein staining showing the representative images of the corneal epithelial defect areas. Data are quantified in the bar graph. (C,D) Slit lamp showed the representative images of corneal haze. Haze-grading data were quantified using a line chart. (E) Mouse eyeballs were harvested at 48 h post-injury. HE staining for the histological structure of cornea wound healing. Scale bar: 250 and 50 μm. (F) Mouse eyeballs were harvested at 48 h post-injury. Immunohistochemical staining showing expression of the proliferation marker Ki-67. Data are shown as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. (Control: normal corneas treated with PBS, CI + PBS: injured corneas treated with PBS, CI + Exo: injured corneas treated with 1 × 10⁶/μl hucMSC-Exos, CI + Exo + AA: injured corneas treated with 1 × 10⁶/μl hucMSC-Exos and 10 μM Rapamycin, CI + Exo + AI: injured corneas treated with 1 × 10⁶/μl hucMSC-Exos and 50 μM Compound C).